Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje Net al.(2024) Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee Lancet Oncol, 25(8), e374-e387 DOI 10.1016/S1470-2045(24)00094-9, PubMed 38821074
Lund T, Gundesen MT, Juul Vangsted A, Helleberg C, Haukås E, Silkjær T, Asmussen JT, Manuela Teodorescu E, Amdi Jensen B, Schmidt Slørdahl T, Nahi H, Waage A, Abildgaard N, Schjesvold F, Nordic Myeloma Study Group(2024) In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease Blood Cancer J, 14(1), 65 DOI 10.1038/s41408-024-01046-2, PubMed 38622134
Nørgaard JN, Moore KLF, Slørdahl TS, Vik A, Tvedt THA, Schjesvold F(2024) VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study Blood Cancer J, 14(1), 60 DOI 10.1038/s41408-024-01047-1, PubMed 38594252